Standout Papers
Citation Impact
Citing Papers
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
2018 StandoutNobel
ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40–Mediated Tumor Rejection
2016 StandoutNobel
Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models
2021
Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy
2016
Checkpoint Blockade Immunotherapy Relies on T-bet but Not Eomes to Induce Effector Function in Tumor-Infiltrating CD8+ T Cells
2014
A sex-biased imbalance between Tfr, Tph, and atypical B cells determines antibody responses in COVID-19 patients
2023 StandoutNobel
Anti–CTLA-4 therapy broadens the melanoma-reactive CD8 + T cell response
2014
VISTA Regulates the Development of Protective Antitumor Immunity
2014
Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity
2015
Anti–CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control
2019
Trastuzumab emtansine (T-DM1) renders HER2 + breast cancer highly susceptible to CTLA-4/PD-1 blockade
2015
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
2019 StandoutNobel
An anti-CTLA-4 heavy chain–only antibody with enhanced T reg depletion shows excellent preclinical efficacy and safety profile
2022
Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy
2022
Confusing signals: Recent progress in CTLA-4 biology
2015
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
2017 StandoutNature
FoxP3+ T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets
2020
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
UV Light Potentiates STING (Stimulator of Interferon Genes)-dependent Innate Immune Signaling through Deregulation of ULK1 (Unc51-like Kinase 1)
2015 StandoutNobel
The promise and challenge of therapeutic genome editing
2020 StandoutNatureNobel
Delivering safer immunotherapies for cancer
2017
Systemic Immunity Is Required for Effective Cancer Immunotherapy
2017
T cell receptor signalling in the control of regulatory T cell differentiation and function
2016
Is autoimmunity the Achilles' heel of cancer immunotherapy?
2017
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
A view on drug resistance in cancer
2019 StandoutNature
Physical Principles of Membrane Shape Regulation by the Glycocalyx
2019 StandoutNobel
Combination cancer immunotherapy and new immunomodulatory targets
2015
The Impact of Tregs on the Anticancer Immunity and the Efficacy of Immune Checkpoint Inhibitor Therapies
2021
CAR-T cells: the long and winding road to solid tumors
2018
Emerging concepts of T cell metabolism as a target of immunotherapy
2016
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
2018
The biology and management of non-small cell lung cancer
2018 StandoutNature
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
2014
Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses
2015
CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors
2020
Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy
2016 StandoutNobel
Identification and functional analysis of heterogeneous FOXP3+ Treg cell subpopulations in human pancreatic ductal adenocarcinoma
2018
CXCR3 expression in regulatory T cells drives interactions with type I dendritic cells in tumors to restrict CD8+ T cell antitumor immunity
2023
The Journey from Discoveries in Fundamental Immunology to Cancer Immunotherapy
2015
Delivery technologies for cancer immunotherapy
2019 Standout
Evolving synergistic combinations of targeted immunotherapies to combat cancer
2015
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
2015
Immune-mediated mechanisms influencing the efficacy of anticancer therapies
2015
Targeting apoptosis in cancer therapy
2020 Standout
Regulatory T cells in cancer immunotherapy
2016 StandoutNobel
Regulatory T Cells: Molecular and Cellular Basis for Immunoregulation
2017
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
2015 Standout
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
2014
Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer
2017
Immune suppressive mechanisms in the tumor microenvironment
2015
Therapeutic vaccines for cancer: an overview of clinical trials
2014
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
2015 StandoutNature
Regulatory T cells in cancer immunotherapy
2014 StandoutNobel
Metal-Organic Framework Nanoparticle-Based Biomineralization: A New Strategy toward Cancer Treatment
2019
Oxidative Damage of DNA Confers Resistance to Cytosolic Nuclease TREX1 Degradation and Potentiates STING-Dependent Immune Sensing
2013
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
2017 StandoutNobel
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
2016
An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells
2020
Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience
2015
FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis
2015
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
2016 StandoutNobel
Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer
2019 StandoutNobel
Hyperprogressive disease: recognizing a novel pattern to improve patient management
2018
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
2023 StandoutNobel
Identification and validation of a tumor-infiltrating Treg transcriptional signature conserved across species and tumor types
2018
Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
2019 Nobel
Roles of regulatory T cells in cancer immunity
2016
Regulatory T Cells and Human Disease
2020 StandoutNobel
Cytoprotective metal-organic frameworks for anaerobic bacteria
2018 StandoutNobel
Targeting Treg cells in cancer immunotherapy
2019 StandoutNobel
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
2014 StandoutNobel
Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events
2017
CTLA-4+ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis
2015
Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging
2015
Development of an Si-Rhodamine-Based Far-Red to Near-Infrared Fluorescence Probe Selective for Hypochlorous Acid and Its Applications for Biological Imaging
2011
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
2018 StandoutNobel
IL-27 gene therapy induces depletion of Tregs and enhances the efficacy of cancer immunotherapy
2018
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
2016 Standout
Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood
2016 StandoutNobel
Spermidine in health and disease
2018 StandoutScience
Imaging bacterial peptidoglycan with near-infrared fluorogenic azide probes
2014 StandoutNobel
Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?
2019
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Copper induces cell death by targeting lipoylated TCA cycle proteins
2022 StandoutScience
Instability of Helios-deficient Tregs is associated with conversion to a T-effector phenotype and enhanced antitumor immunity
2016
Unique potential of 4-1BB agonist antibody to promote durable regression of HPV + tumors when combined with an E6/E7 peptide vaccine
2015 StandoutNobel
The future of immune checkpoint therapy
2015 StandoutScienceNobel
Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy
2013
Influence of immunoglobulin isotype on therapeutic antibody function
2016
Emerging Opportunities and Challenges in Cancer Immunotherapy
2016
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Proenkephalin+regulatory T cells expanded by ultraviolet B exposure maintain skin homeostasis with a healing function
2020 StandoutNobel
Epigenetic conversion of conventional T cells into regulatory T cells by CD28 signal deprivation
2020 StandoutNobel
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
2016 StandoutNobel
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells
2021 StandoutNobel
PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance
2020
Neoantigens in cancer immunotherapy
2015 StandoutScience
Nanoparticle-Based Immunotherapy for Cancer
2014
Local checkpoint inhibition of CTLA‐4 as a monotherapy or in combination with anti‐PD1 prevents the growth of murine bladder cancer
2016
Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy
2022
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer
2013
Whole Tumor Antigen Vaccines: Where Are We?
2015
Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity
2014
OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy
2014
Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab
2017
CAR T cell immunotherapy for human cancer
2018 StandoutScience
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Regulatory T cells expressing abundant CTLA‐4 on the cell surface with a proliferative gene profile are key features of human head and neck cancer
2018 StandoutNobel
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
2017 StandoutNobel
Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients
2014
Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody
2018 StandoutNobel
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
2015
Works of Frederick Arce being referenced
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
2013 StandoutNobel
Hypochlorous Acid: A Natural Adjuvant That Facilitates Antigen Processing, Cross-Priming, and the Induction of Adaptive Immunity
2009
Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1
2013
A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice
2014